• 1mg, 2mg and 4mg tablets

• MR formulations are not approved

• 500microgram tablets

• Capsules: 500micrograms

• Tablets: 5mg

• MR Tablets - 7.5mg, 15mg

• Capsules: 20mg, 40mg
• Moderate to severe stress incontinence in combination with supervised pelvic floor excercises only

•  MR Tablets - 4mg, 8mg

• Tablets: 15mg

• Tablets: 20mg

• Approved for use when antimuscarinics don’t work, are not suitable or side effects are unacceptable, in line with NICE guidance. 

• Oxybutinin patch 36mg (releases approximately 3.6mg in 24 hours). 
• Approved for patients in whom two antimuscarinics have proved to be efficacious but the side effects are intolerable, or for patients who cannot swallow tablets.

• Methylphenidate is approved for use as a third line option (after e.g. antimuscarinics, imipramine, and pelvic floor exercises) in the treatment of giggle incontinence in children. Its use should be subject to a therapeutic trial to be reviewed after two months and considered for Shared Care if patients have been shown to respond after the trial period.

• The following methylphenidate formulations are approved for giggle incontinence:
  
  • 5mg & 10mg tablets.
  • 10mg, 20mg & 30mg m/r capsules (Equasym XL®).
  • 18mg, 27mg & 36mg m/r tablets (Xaggitin® XL)

• Existing patients who are prescribed Concerta® XL should be reviewed and switched to Xaggitin® XL as appropriate
• Xaggitin® XL is bioequivalent to Concerta® XL
• The effects of Equasym® XL last for about 8 hours compared with about 12 hours for Xaggitin® XL. 

• Vaginal Devices for female stress urinary incontinence (e.g. Diveen, Contiform, Efemia)
• Approved for use in line with NTAG / NICE
• Product should only be initiated by a specialist pelvic health physiotherapists and specialist nurses

• 10mg, 25mg and 50mg tablets
• 25mg in 5ml sugar-free oral solution is also approved for use.
•  Green plus for the treatment of nocturnal enuresis in children aged 6 years and above when organic pathology, including spina bifida and related disorders, have been excluded and no response has been achieved to all other non-drug and drug treatments, including antispasmodics and vasopressin-related products.Should only be prescribed by a healthcare professional with expertise in the management of persistent enuresis

• The following formulations are approved:
  
  • 100microgram and  200 microgram tablets;
  • 120 microgram sublingual tablets. 
  
  
• Note: nasal formulations no longer licensed for treating nocturnal
  enuresis (see section 6.5.2 for other formulations).

• Oral lyophilisates: 25microgram, 50 microgram

• 10mg and 25mg tablets
• 25mg in 5ml syrup is also approved. unlicensed.

• Prefilled syringe: 120mg/50ml

• potassium citrate 3g & citric acid 500mg in 10ml

Note: for the treatment of  mild cystitis potassium citrate mixture is suitable for self-care.

• 100mg capsules

• Approved for treating bladder pain in line with NICE

• For instillation into the bladder.

• Ialuril® is a 50ml solution for instillation into the bladder approved as second line treatment in patients who have failed Cystistat.

• Approved the treatment of:
  
  
  
  • Interstitial cystitis/painful bladder syndrome
  
  
  • Radiation cystitis
  
  
  • Recurring bacterial cystitis
  
  
  • Overactive bladder
  
  
  
  

• 1.5% large volume solutions (up to 3 litres).

• Large volume solutions (up to 3 litres).

• Large volumes  - up tp 3 litres.

• Whitmore cocktail is a 60ml bladder installation containing hydrocortisone 100mg, heparin Sodium 10,000units, and bupivacaine 50mg in Sodium Chloride 0.9%.

• Chlorhexidine 0.02% (1 in 5,000) solution in 100ml sachets.

• Sodium chloride 0.9% solution in 100ml sachets.

• Solution R 2 x 30ml sachets (citric acid 6%, gluconolactone 0.6%, magnesium carbonate 2.8%, disodium edetate 0.01%)

• Solution G 2 x 30ml sachets (citric acid 3.23%, magnesium oxide 0.38%,
  sodium bicarbonate 0.7%, disodium edetate 0.01%)

• 10mg and 20mg tablets
  • Approved for the treatment of erectile dysfunction
  • Also approved for specialist use in treating secondary Raynaud's disease. 
• 5mg tablets (once daily) 
  • Approved for the treatment of erectile dysfunction (in accordance with SLS criteria)

• 5mg, 10mg and 20mg tablets

• Vitaros® 3mg/g cream
• Muse® 500microgram, and 1mg.

Treatment with alprostadil cream (Vitaros®) is NOT approved for use in County Durham and Tees Valley

• 25microgram/phentolamine 2mg solution for injection. 
• Approved as first choice intracavernosal injection option.

• Approved as the second choice intracavernosal injection option.
• Caverject® 10 & 20 microgram injections (Caverject® dual chamber injections are easier to use and less expensive than the vials).
• Viridal Duo® 10, 20 and 40 microg starter pack and dual chamber injection (approved for use whilst supply issues surrounding Caverject® are ongoing).